Core Viewpoint - Lisata Therapeutics has formed a strategic collaboration with GATC Health to leverage artificial intelligence in drug discovery, specifically focusing on the lead candidate certepetide and exploring potential new drug combinations [1][2][3] Collaboration Details - GATC Health is recognized for its expertise in AI-driven drug discovery and has been selected by Lloyd's of London for clinical trial insurance, highlighting its credibility [2][3] - The collaboration aims to optimize the development of certepetide for pancreatic cancer and explore its use in combination with other anti-cancer agents or drugs from different therapeutic areas [3][5] Technology and Speed - GATC's technology can perform billions of calculations rapidly, which is expected to accelerate drug development, reduce risks, and lower costs [4] - Both companies emphasize a responsive working relationship, allowing for quick decision-making and implementation [4] Development Strategy - The initial phase involves analyzing certepetide using GATC's advanced technology platform, with future plans to identify other drugs for combination therapy [5][8] - The collaboration is anticipated to enhance Lisata's pipeline by potentially introducing new drug candidates and therapeutic areas [5][6] Clinical Pipeline Progress - Lisata has reported progress in its clinical pipeline, including encouraging preliminary data from the Phase 2b pancreatic cancer trial, which is expected to support the development strategy moving forward [7][10] - The company is also preparing to release data from various trials, including the ASCEND trial, which has shown positive therapeutic effects [9][11] Future Outlook - 2025 is projected to be a data-rich year for Lisata, with expectations for significant clinical data releases and ongoing discussions with regulatory agencies and potential partners to maximize the value of certepetide [9][12]
Lisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMI